NCT05058014
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 22 Years and older (Adult, Older Adult)
Location of Metastases: Bone
Additional Notes: 
Exclusions: Patients with asymptomatic bone lesions that do note require an intervention
https://ClinicalTrials.gov/show/NCT05058014